Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas; a Randomized Phase II Clinical Trial

Who is this study for? Patients with Soft Tissue Sarcomas
What treatments are being studied? Pre-Operative Radiotherapy
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Currently, soft tissue sarcomas (STS) are preoperatively irradiated in a conventionally fractionated regimen of 25 x 2 Gy in five weeks. Recent radiobiological investigations, however, suggest sensitivity to (modest) hypofractionation. Within this study, patients will be randomized to receive either the conventional schedule of 25 x 2 Gy or a shorter preoperative regimen of 14 x 3 Gy, in the hypothesis that both the postoperative wound complication rate until 30 days after surgery, as well as the local control probability at two years are comparable in both arms.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area, for which the standard treatment is a combination of and radiotherapy and surgery (deep seated and/or \> 5cm in largest tumor diameter and/or an anticipated close resection margin and/or grade II/III according to the FNCLCC definition);

• • Absence of regional and/or distant disease. Patients staged by at least a CT scan of the chest (. Staging may also be performed by FDG-PET scanning and or total body MRI scans. Patients with an uncertain metastatic status (e.g. small indifferent lung nodules) and patients with a low metastatic burden not precluding the application of both preoperative radiotherapy and definitive surgery, are allowed to participate;

• WHO Performance Status ≤ 2;

• Able and willing to undergo preoperative radiotherapy;

• Able and willing to undergo definitive surgery;

• Able and willing to comply with regular follow-up visits;

• Able and willing to complete patient reported outcome questionnaires (health-related quality of life and cost effectiveness);

• • Able and willing to undergo randomization;

• Age ≥ 18 years;

• Signed written informed consent

Locations
Other Locations
Netherlands
Universitair Medisch Centrum Groningen
RECRUITING
Groningen
Leids Universitair Medisch Centrum
RECRUITING
Leiden
Radboudumc
RECRUITING
Nijmegen
Erasmus Medical Centre
RECRUITING
Rotterdam
Contact Information
Primary
Rick Haas, MD, PhD
r.haas@nki.nl
+315129111
Backup
Astrid Scholten, MD, PhD
a.scholten@nki.nl
031 20 512 9111
Time Frame
Start Date: 2021-06-25
Estimated Completion Date: 2031-05-01
Participants
Target number of participants: 168
Treatments
Active_comparator: 25x2Gy
the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
Experimental: 14x3Gy
the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
Related Therapeutic Areas
Sponsors
Leads: The Netherlands Cancer Institute
Collaborators: Leiden University Medical Center

This content was sourced from clinicaltrials.gov